By Max Klietmann, VP of Marketing, LSN
Recently, I wrote a feature detailing the increasing number of non-VC entities investing in early stage biotech companies. Due to the interest that article generated, we’ve decided to follow on with another LSN Investor Database Feature; this edition will focus on the early-stage investor interest in the medtech arena.
As mentioned in the previous feature, LSN’s investor research group maintains quarterly contact with over 5,000 active investors in the life science space, with a particular focus on those categories filling the void left by Venture Capital. This gives LSN unprecedented insight into what private investor trends look like today and going forward.
The chart below shows the results of an LSN Investor Database search mapping out all non-venture capital investors tracked by LSN with a declared interest – or mandate – in seed/venture stage medical technology companies with a prototype or early-stage clinical asset. The result is 561 investors globally. This should be very encouraging news to the executives of a space that has seen a great deal of turbulence in recent years in terms of fundraising trends.
So what’s the next step? If you’re an early-stage medtech looking to raise money, these investor categories should certainly be on your radar. Second, do your homework on how exactly these categories behave in terms of investment activity. LSN’s research team can help elucidate this information on an investor-by investor basis. Finally, the space is in flux, so stay tuned as LSN continues to offer insights on the changing medical technology investor landscape.